Cocaine HCl, supplied by the National Institute of Drug Abuse (Research Triangle Institute, Research Triangle Park, NC), was diluted in 0.9% NaCl (saline; SAL) to a concentration of 1.6 mg/ml and then refrigerated. Heparin (5 USP/ml) was added to the cocaine solution to aid catheter patency. The syringe pump in the experimental chamber delivered 0.025 ml/s, and the duration of the pump was set to provide 0.3 mg/kg/infusion. Progesterone (Sigma-Aldrich, St. Louis, MO) was dissolved to 0.625 mg/ml in peanut oil (USP; Sigma-Aldrich) as a vehicle (VEH) and administered subcutaneously (SC) at a 0.5 mg/kg dose. Atomoxetine (Sigma-Aldrich) was dissolved in saline (SAL; 30 mg/ml) and delivered intraperitoneally (IP) at a 1.5 mg/kg dose. PRO, ATO, and control treatments (VEH or SAL) were administered approximately 30 min prior to the start of experimental sessions. The PRO dose was based on previous work that found it was effective in reducing cocaine and cue-primed reinstatement as well as reducing breakpoints for cocaine on a progressive ratio schedule (e.g., Larson et al. 2007 (link); Zlebnik et al. 2014 (link)). The ATO dose was selected based on previous research showing it reduced cocaine seeking (Swavle et al. 2016 ; Zlebnik and Carroll 2014 (link)) and impulsive choice at doses of 1–2 mg/kg (e.g., Bizot et al. 2011 (link); Robinson et al. 2008 ).